Rat strain differences in the vulnerability of serotonergic nerve endings to neurotoxic damage by p-chloroamphetamine

Ali SF, Tandon P, Tilson HA, Lipe GW, Newport GD, Slikker W (1990) Intracerebral and oral administration of methylenedioxymetamphetamine (MDMA): distribution and neurochemical alterations in rat brain. Eur J Pharmacol 183: 450–458 Allen RP, MacCann UD, Ricaurte GA (1993) Persistent effects of (+)-3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) on human sleep. Sleep 16: 560–564 Aulakh CS, Wozniak KM, Hill JL, Devane CL, Tolliver TL, Murphy DL (1988) Differential neuroendocrine responses to the 5-HT agonist m-CPP in Fawn-Hooded rats relative to Wistar and Sprague-Dawley rats. Neuroendocrinology 48: 401–406 Aulakh CS, Hill JL, Murpht DL (1989) A comparison of feeding and locomotion responses to serotonin agonists in three rat strains. Pharmacol Biochem Behav 31: 567–571 Barnes DM (1988) New data intensify the agony over ecstasy. Science 239: 864–866 Battaglia G, Ye SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987) 3,4 Methylenedioxymethamphetamine and 3,4,methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]-paroxetine-labelled serotonin uptake sites. J Pharmacol Exp Ther 242: 911–916 Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4 methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159–163 Battaglia G, Sharkey J, Kuhar MJ, De Souza EB (1991) Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA. Synapse 8: 249–260 Berger UV, Grzanna R, Molliver ME (1990) Unlike systemic administration of PCA, direct intracerebral injection does not cause neurotoxicity on 5-HT axons. Exp Neurol 109: 257–268 Berger UV, Gu XF, Azmitia EC (1992a) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, para-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine relase via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215: 153–160 Berger UV, Grzanna R, Molliver ME (1992b) The neurotoxic effects of p-chloroamphetamine in rat-brain are blocked by prior depletion of serotonin. Brain Res 578: 177–185 Berger UV, Gu XF, VanLange JWL, Azmitia EC (1992c) Evidence for a common mechanism of serotonin release induced by substitued amphetamines in vitro. Ann NY Acad Sci 648: 358–360 Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, Holson RR (1992) The influence of environmental temperature on the transient effect of methamphetamine neurotoxicity. J Pharmacol Exp Ther 260: 817–824 Bowyer JV, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr, Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268: 1571–1580 Brodkin J, Malyala A, Nash F (1993) Effects of acute monoamine depletion on 3,4-MDMA-induced neurotoxicity. Pharmacol Biochem Behav 45: 647–653 Broening HW, Bacon L, Slikker W (1994) Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-MDMA. J Pharmacol Exp Ther 271: 285–293 Colado MI, Murray TK, Green AR (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108: 583–589 Cash CD, Vayer P, Mandel P, Maitre M (1985) Tryptophan 5-hydroxylase. Rapid purification from whole brain and production of a specific antiserum. Eur J Biochem 149: 239–245 Commins DL, Axi KJ, Vosmer G, Seiden LS (1987) Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of parachloroamphetamine. Brain Res 419: 253–261 Crino PB, Vogt BA, Chen JC, Volicer L (1989) Neurotoxic effects of partially oxidized serotonin: tryptamine-4,5-dione. Brain Res 504: 247–254 De Vito M, Wagner GC (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28: 1145–1150 Edwards G (1989) Blasted with ennui: dangers in another drug fashion. Br Med J 298: 136 Emery D, Engel J, Larsson K (1980) Rat strain differences in brain monoamine metabolism following para-chlorophenylalanine treatment. Pharmacol Biochem Behav 12: 311–312 Finnegan KT, Skratt JJ, Irwin I, Langston JW (1990) The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of MDMA in rats. Neurosci Lett 195: 300–306 Habert E, Graham D, Tahraoui L, Claustre Y, Langer SZ (1985) Characterisation of [3H]-paroxetine binding to rat cortical membranes. Eur J Pharmacol 118: 107–114 Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“Ecstasy”). Lancet 340: 384–387 Hewitt KE, Green AR (1994) Chrloromethanol, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA to rats. Neuropharmacology 33: 1589–1595 Hirai M, Nakajima T (1979) Biochemical studies on the mechanisms of difference in the renal toxicity of 5-hydroxytryptophan between Sprague-Dawley and Wistar rats. J Biochem 86: 907–913 Hirata H, Ladenheim B, Rothman RB, Epstein Ch, Cadte JL (1995) Methamphetamineinduced serotonin neurotoxicity is mediated by Superoxide radicals. Brain Res 677: 345–347 Huether G, Hajak G, Reimer A, Poeggeler B, Blömer M, Rodenbeck A, Rüther E (1992) The metabolic fate of infused L-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites. Psychopharmacol 109: 422–432 Hulihan-Giblin BA, Park YD, Goldman D, Aulakh CS (1993) Analysis of the 5-HT1C-receptor and the serotonin uptake site in fawn-hooded rat brain. Eur J Pharmacol 239: 99–102 Kacew S, Fesling MFW (1996) Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occuring substances. J Toxicol Environ Health 47: 1–30 Leonard BE, Tuite M (1981) Anatomical, physiological and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 22: 251–286 Lopez JF, Chalmers DT, Vazquez DM, Watson SJ, Akil H (1994) Serotonin transporter mRNA in rat brain is regulated by classical antidepressants. Biol Psychiatry 35: 287–290 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275 Mamounas LA, Mullen CA, O'Hearn E, Molliver ME (1991) Dual serotonergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314: 558–586 McCann UD, Ricaurte GA (1991) Major metabolites of (±)3,4-methylene-dioxyamphetamine (MDA) do not mediate its toxic effects on brain-serotonin neurons. Brain Res 545: 279–282 McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). J Neurochem 54: 14–22 Molliver ME, Berger UV, Mamounas LA, Molliver DL, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600: 640–661 Nash JF, Arora RC, Schreiber MA, Meltzer HY (1991) Effect of 3,4-methylenedioxymethamphetamine of [3H]-paroxetine binding in the frontal cortex and blood platelets of rats. Biochem Pharmacol 41: 79–84 O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788–2803 Paris JM, Cunningham KA (1992) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res Bull 28: 115–119 Peroutka SJ (1987) Incidence of recreational use of 3,4-methylene dioxymethamphetamine (MDMA, “Ecstasy”) on an undergraduate campus. N Engl J Med 317: 1542–1543 Price LH, Ricaurte GA, Grystal JH, Henninger GR (1989) Neuroendocrine and mood responses in intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen Psychiatry 46: 20–22 Riachi NJ, Behrand RA, Harik SI (1991) Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the brain and blood-brain barrier in vitro in five rat strains. Brain Res 555: 19–24 Ricaurte GA, Forno LS, Wilson MA, DeLanney LEW, Irwin I, Molliver ME, Langston JW (1988) (±)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260: 51–55 Ricaurte GA, Finnegan T, Irwin I, Langston JW (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA. Preliminary observations. Ann NY Acad Sci 600: 699–710 Rudnick G, Wall SC (1992) The molecular mechanism of exstasy [3,4-methylenedioxymethaamphetamine (MDMA)]. Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89: 1817–1821 Sanders-Bush E, Bushing JA, Sulser F (1972) Chloroamphetamine-inhibition of cerebral tryptophan hydroxylase. Biochem Pharmacol 21: 150–11510 Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990) Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT, receptors. Brain Res 529: 85–90 Schmidt CJ, Black CK, Taylor VL (1991) L-Dopa potentiation of serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Eur J Pharmacol 203: 41–49 Slikker W, Ali SF, Scallet AC, Frith CH, Newport GD, Beiley JR (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 94: 448–457 Stone DM, Stahl DC, Hanson GR, Gibb JW (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128: 41–48 Stone DM, Merchant KM, Hanson GR, Gibb JW (1987a) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin pathways in brain of rat. Neuropharmacol 26: 1677–1683 Stone DM, Hanson GR, Gibb JW (1987b) Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacol 26: 1657–1661 Stone DM, Johnson M, Hanson GR, Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4 methylenedioxymethamphetamine. J Pharmacol Exp Ther 247: 79–87 Urca G, Segen S, Same Y (1985) Footshock-induced analgesia: its opioid nature depends on the strain of rat. Brain Res 329: 109–116 Wang P, Aulakh CS, Hill JL, Murphy DL (1988) Fawn-hooded rats are subsensitive to the food intake suppressant effects of 5-HT agonists. Psychopharmacol 94: 558–562 Wilson MA, Ricaurte GA, Molliver ME (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neurosci 28: 121–137 Zhou D, Huether G, Wiltfang J, Hajak G, Rüther E (1996) Serotonin transporters in the rat frontal cortex: lack of circadian rhythmicity but down-regulation by food restriction. J Neurochem 67: 656–661